360° SearchNetwork Hot Spots Trends Time Series

Advanced Search Options >>

Swedish Orphan Biovitrum AB

Type: Company

Name: Swedish Orphan Biovitrum AB (Biovitrum AB)

Nationality: Sweden

Web Address: http://www.biovitrum.com/

Fact Sheet: Fact Sheet for Biovitrum AB

First reported May 17 2013 - Updated May 17 2013 - 3 reports

Ortivus AB

Sobi names Mats-Olof Wallin as permanent CFO

5 minutes ago, 7:33am (ET) 05/17/2013 M2Swedish Orphan Biovitrum AB (Sobi) (STO: SOBI.ST) announced today the appointment of Mats-Olof Wallin as senior vice president and CFO of the company.Wallin most recently was the interim CFO of the company. Prior ... [Published Zecco - May 17 2013]

Entities: Swedish Orphan Biovitrum AB, Pharmacia Corporation, Ortivus AB, Biotage AB

First reported May 16 2013 - Updated May 16 2013 - 2 reports

Pharming reports on financial results first quarter 2013

LEIDEN, NETHERLANDS -- (Marketwired) -- 05/16/13 -- Biotech company Pharming Group NV("Pharming" or "the Company") (NYSE Euronext: PHARM) todaypublished itsfinancial report for the three months ended 31 March 2013.FINANCIAL HIGHLIGHTS* Revenues and other ... [Published Equities.com - May 16 2013]

Entities: Pharming Group NV, Ruconest, Hereditary Angioedema, Convertible Bonds, Swedish Orphan Biovitrum AB

First reported May 16 2013 - Updated May 16 2013 - 1 reports

Swedish Orphan Biovitrum AB

Pharming Group Q1 Loss Narrows - Quick Facts

Pharming Group NV (PHGUF.PK) reported that its first-quarter net loss narrowed to 5.4 million euros from 6.5 million euros prior year.Revenues and other income decreased to 0.5 million euros from 1.0 million euros prior year. The company said the decline ... [Published RTTNews.com - May 16 2013]

Entities: Pharming Group NV, Ruconest, Swedish Orphan Biovitrum AB

First reported May 16 2013 - Updated May 16 2013 - 1 reports

FDA Receives Biogen Idec's Biologics License Application for Factor VIII Therapy for Hemophilia A

Biogen Idec announced that the U.S. Food and Drug Administration (FDA) has accepted the company's Biologics License Application (BLA) for the marketing approval of ELOCTATE (recombinant factor VIII Fc fusion protein) for the treatment of hemophilia A ... [Published Individual.com - May 16 2013]

Entities: Hemophilia A, ELOCTATE, Biologics License Application, Factor VIII, Biogen Idec Inc

First reported May 14 2013 - Updated May 14 2013 - 2 reports

Biogen Idec Inc

FDA starts review of Biogen Idec's haemophilia A therapy

Could gain US approval by the first quarter of 2014The US FDA has started the review process for Biogen Idec's long-acting haemophilia drug Eloctate, setting up a possible approval in the first quarter of 2014.The company filed for approval of Eloctate ... [Published PMLive - May 14 2013]

Entities: Hemophilia A, ELOCTATE, Hemophilia, Biogen Idec Inc

First reported Apr 29 2013 - Updated Apr 29 2013 - 1 reports

Boehringer Ingelheim GmbH

4/29/13 - Sobi publishes Report for the First Quarter 2013

Release date- 26042013 - Swedish Orphan Biovitrum AB (publ) (Sobi) today announced its results for the first quarter 2013.Revenues for the quarter totalled MSEK 528.5 (506.7), with continued momentum across the commercial portfolio and several significant ... [Published Pharmacy Choice - Apr 29 2013]

Entities: Swedish Orphan Biovitrum AB, Hemophilia, Geoffrey McDonough, Boehringer Ingelheim GmbH, Recombinant

First reported Apr 19 2013 - Updated Apr 19 2013 - 1 reports

Biotage AB

Swedish Orphan Biovitrum appoints new interim CFO

Swedish Orphan Biovitrum AB, or Sobi, a biopharmaceutical company, has appointed Mats-Olof Wallin as interim CFO. Wallin - until recently the CFO of Swedish biotech company Biotage AB - brings more than 30 years of experience in the pharmaceutical industry, ... [Published Individual.com - Apr 19 2013]

Entities: Swedish Orphan Biovitrum AB, Appointed, Biotage AB

First reported Apr 17 2013 - Updated Apr 17 2013 - 5 reports

Invitation - Presentation of Sobi's first quarter results 2013 (Swedish Orphan Biovitrum AB (publ))

On April 26, at 08:00 CET, Swedish Orphan Biovitrum AB (Sobi) will publish its interim report for the first quarter, 2013.Financial analysts and media are invited to participate in a telephone conference, which will include a presentation of the results, ... [Published Presscontacts.com - Apr 17 2013]

Entities: Swedish Orphan Biovitrum AB, Investor Relations, Geoffrey McDonough

First reported Feb 23 2013 - Updated Feb 23 2013 - 1 reports

Exelixis, Sobi ink 3-year pact to distribute and commercialise medullary thyroid cancer drug 'Cometriq' in EU

Biotechnology company, Exelixis, Inc., and international specialty healthcare company, Swedish Orphan Biovitrum (Sobi) have entered into a three-year agreement to support the distribution and commercialisation of Cometriq (cabozantinib) for metastatic ... [Published PharmaBiz - Feb 23 2013]

Entities: Exelixis Inc, Swedish Orphan Biovitrum AB, medullary thyroid cancer, Metastatic, antineoplastic

First reported Feb 21 2013 - Updated Feb 21 2013 - 1 reports

Sobis ytterligare emission om 200 Mkr under nuvarande obligationslån fulltecknad

Som tidigare kommunicerats har styrelsen för Swedish Orphan Biovitrum AB (Sobi)beslutat om att emittera ytterligare belopp under nuvarande obligationslån meden låneram om 1.000 Mkr. Emissionen om 200 Mkr nominellt belopp är nufulltecknad.Nordea Bank agerar ... [Published GlobeNewswire - Feb 21 2013]

Entities: Swedish Orphan Biovitrum AB, Emission, Nordea Bank AB

First reported Feb 11 2013 - Updated Feb 11 2013 - 1 reports

Biogen, Sobi report positive data from recombinant Fc fusion proteins studies

Biogen Idec and Swedish Orphan Biovitrum (Sobi) have reported new Phase 3 data supporting the long-lasting protection capability of recombinant factors VIII Fc fusion protein (rFVIIIFc) and IX Fc fusion protein (rFIXFc) from bleeding in patients with ... [Published PBR - News - Feb 11 2013]

Entities: Swedish Orphan Biovitrum AB, Recombinant, Protein, fusion protein

First reported Jan 18 2013 - Updated Jan 18 2013 - 1 reports

Flaggningsmeddelande i Swedish Orphan Biovitrum AB (publ)

Anmälan om förvärv av eller överlåtelse av aktier eller depåbevisEmittent 556038-9321 Swedish Orphan Biovitrum AB (publ)Instrument SE0000872095 Ordinary sharesInnehavare MPM CapitalFöre ... [Published GlobeNewswire - Jan 18 2013]

Entities: Swedish Orphan Biovitrum AB, MPM Capital, Ordinary Shares

Quotes

...) where he held the role of CFO between 2003 and 2011. Wallin has been working at Sobi for the past several months. "We are very pleased with the appointment of Mats-Olof as our permanent CFO. We have conducted a thorough search process and Mats-Olof has emerged as the most suitable candidate for the job. He brings significant experience to the role and has already proven to be a great addition to our senior team" , said CEO Geoffrey McDonough. --- About Sobi Sobi is an international specialty healthcare company dedicated to rare diseases...

Sobi appoints Mats-Olof Wallin as permanent Chief Financial Officer [Published NASDAQ OMX - May 17 2013]

...Glenn Pierce, M D , Ph D , senior vice president of Global Medical Affairs and chief medical officer of Biogen Idec's hemophilia therapeutic area. "For those people currently on preventative--or prophylactic--treatment, ELOCTATE provides the potential to reduce the number of intravenous injections by 50 to 100 per year."

FDA Receives Biogen Idec's Biologics License Application for Factor VIII Therapy for Hemophilia A [Published Individual.com - May 16 2013]

...could cause actual results or events to differ from the forward-looking statements that we make, see the sections entitled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2013...

Savient Pharmaceuticals Reports First Quarter 2013 Financial Results [Published Barchart - May 15 2013]

...an important new treatment option for patients with this disease," said Michael Morrissey, president and chief executive officer of Exelixis. "While we continue to execute on the commercial launch, we remain focused on advancing the cabozantinib clinical development program. The majority of sites for the COMET program, consisting of two pivotal trials in CRPC, are now open, and we continue to expect top-line data in 2014. Beyond prostate cancer, we expect to start additional pivotal trials in metastatic renal cell carcinoma and metastatic hepatocellular carcinoma in the third quarter 2013. In addition, we have a broad and expanding program of earlier stage trials, and updates on some of these trials will be provided at the ASCO Annual Meeting in June."

Exelixis Issues 1Q 2013 Financial Results [Published Individual.com - May 10 2013]

More Content

sort by: Date \| Relevance
Novo Nordisk Reports Promising Phase III Result... [Published Genetic Engineering News - May 17 2013]
Sobi names Mats-Olof Wallin as permanent CFO [Published Zecco - May 17 2013]
Sobi appoints Mats-Olof Wallin as permanent Chi... [Published Marketwire - Breaking News Releases - May 17 2013]
Sobi appoints Mats-Olof Wallin as permanent Chi... [Published NASDAQ OMX - May 17 2013]
Sobi appoints Mats-Olof Wallin as permanent Chi... [Published Zecco - May 17 2013]
Pharming reports on financial results first qua... [Published Equities.com - May 16 2013]
Pharming Group Q1 Loss Narrows - Quick Facts [Published RTTNews.com - May 16 2013]
Pharming reports on financial results first qua... [Published Reuters - May 16 2013]
FDA Receives Biogen Idec's Biologics License Ap... [Published Individual.com - May 16 2013]
HP&M Director Frank Sasinowski Receives NORD Li... [Published FDA Law Blog - May 15 2013]
Savient Pharmaceuticals Reports First Quarter 2... [Published Barchart - May 15 2013]
FDA starts review of Biogen Idec's haemophilia ... [Published PMLive - May 14 2013]
US FDA accepts Biogen Idec's Eloctate BLA for t... [Published PharmaBiz - May 14 2013]
Exelixis Issues 1Q 2013 Financial Results [Published Individual.com - May 10 2013]
Exelixis Reports First Quarter 2013 Financial R... [Published Individual.com - May 10 2013]
Exelixis' CEO Discusses Q1 2013 Results - Earni... [Published Seeking Alpha - May 08 2013]
Exelixis Announces First Quarter 2013 Financial... [Published Business Wire - May 07 2013]
Q1 2013 Earnings Call - Swedish Orphan Biovitru... [Published Research and Markets - Apr 29 2013]
4/29/13 - Sobi publishes Report for the First Q... [Published Pharmacy Choice - Apr 29 2013]
Download presentation- Evolving the Orphan Inno... [Published Terrapinn - Apr 29 2013]
Resolutions from Sobi's Annual General Meeting ... [Published GlobeNewswire: Acquisitions News - Apr 26 2013]
Kommuniké från Sobis årsstämma [Published GlobeNewswire: Acquisitions News - Apr 26 2013]
Sobi publicerar resultaten för första kvartalet... [Published GlobeNewswire: Advertising News - Apr 26 2013]
Sobi publishes Report for the First Quarter 2013 [Published GlobeNewswire: Advertising News - Apr 26 2013]
Swedish Orphan Biovitrum appoints new interim CFO [Published Individual.com - Apr 19 2013]
Media Release Interim Report as of March 31, 2013 [Published Noodls - Apr 18 2013]
BB BIOTECH AG: Biotech sector maintains upward ... [Published FinanzNachrichten.de - Apr 18 2013]
Biotech sector maintains upward trend in first ... [Published Zecco - Apr 18 2013]
Invitation - Presentation of Sobi's first quart... [Published Presscontacts.com - Apr 17 2013]
Invitation - Presentation of Sobi's first quart... [Published Yahoo! Finance - Apr 17 2013]

Blogs

sort by: Date \| Relevance
HP&M Director Frank Sasinowski Receives NORD Li... [Published FDA Law Blog - May 15 2013] Earlier this week, the National Organization for Rare Disorders (“NORD”) held its annual gala here in Washington, D.C. recognizing achievements and advances in the area of rare (orphan) diseases. Of course, this year is extra special; it’s the 30th anniversary ...
Biogen, Sobi report positive data from recombin... [Published PBR - News - Feb 11 2013] Biogen Idec and Swedish Orphan Biovitrum (Sobi) have reported new Phase 3 data supporting the long-lasting protection capability of recombinant factors VIII Fc fusion protein (rFVIIIFc) and IX Fc fusion protein (rFIXFc) from bleeding in patients with ...
4 Healthcare Stock Stories for Weekend Wellness [Published Wall St. Cheat Sheet - Feb 09 2013] Bristol-Myers Squibb Company ( NYSE:BMY ) Closing price $36.97 On Friday, The Medicines Company said that the global license and two-year collaboration with Bristol-Myers Squibb for Recothrom, a recombinant thrombin okayed by the FDA accord which ...
US EQUITIES OPENING HEADLINES INCLUDING: St Jud... [Published Proactiveinvestors United Kingdom website - Feb 08 2013] US equities look set to open broadly unchanged with a lack of tier-1 macroeconomic data driving the markets in early European trade. NASDAQ futures are seen to be supported by Apple after the company announced yesterday they are in talks to return ...

Press Releases

sort by: Date \| Relevance
Sobi appoints Mats-Olof Wallin as permanent Chi... [Published Marketwire - Breaking News Releases - May 17 2013]
Exelixis Announces First Quarter 2013 Financial... [Published Business Wire - May 07 2013]
Resolutions from Sobi's Annual General Meeting ... [Published GlobeNewswire: Acquisitions News - Apr 26 2013]
Kommuniké från Sobis årsstämma [Published GlobeNewswire: Acquisitions News - Apr 26 2013]
Sobi publicerar resultaten för första kvartalet... [Published GlobeNewswire: Advertising News - Apr 26 2013]